Palisade Bio financials
$1.45−3.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 100.0% | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$11.7M | -$10.7M | -$10.0M | -$2.9M | -$2.8M | -$2.3M | -$3.4M | -$3.6M | -$4.2M | -$3.7M | -$3.2M | -$3.8M |
| Net income | -$10.6M | -$9.6M | -$8.9M | -$2.9M | -$2.8M | -$2.2M | -$3.3M | -$3.5M | -$4.1M | -$3.5M | -$3.0M | -$3.6M |
| Net margin | −2114.8% | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.05 | $-0.05 | $-0.04 | $-0.38 | $-0.58 | $-0.47 | $-1.54 | $-2.32 | $-3.32 | $-4.59 | $-4.80 | $-7.38 |
| EBITDA | -$11.7M | -$10.7M | -$10.0M | -$2.9M | -$2.8M | -$2.3M | -$3.4M | -$3.6M | -$4.2M | -$3.7M | -$2.9M | -$3.8M |
| Operating cash flow | -$7.6M | -$3.9M | -$3.1M | -$3.6M | -$1.8M | -$2.3M | -$2.4M | -$3.1M | -$3.5M | -$3.2M | -$2.7M | -$2.7M |
| Free cash flow | -$7.6M | -$3.9M | -$3.1M | -$3.6M | -$1.8M | -$2.3M | -$2.4M | -$3.1M | -$3.5M | -$3.2M | -$2.7M | -$2.7M |
| Diluted shares | 211.4M | 209.7M | 205.6M | 7.5M | 4.8M | 4.8M | 2.2M | 1.5M | 1.2M | 0.8M | 0.6M | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $125.2M | $132.6M | $133.4M | $5.2M | $5.4M | $7.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $127.3M | $133.3M | $134.3M | $7.0M | $6.7M | $8.2M |
| Total liabilities | $5.6M | $6.0M | $5.0M | $3.8M | $4.0M | $2.9M |
| Shareholders' equity | $121.7M | $127.4M | $129.4M | $3.2M | $2.6M | $5.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology